1. Home
  2. CYTK vs KNSL Comparison

CYTK vs KNSL Comparison

Compare CYTK & KNSL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cytokinetics Incorporated

CYTK

Cytokinetics Incorporated

HOLD

Current Price

$62.51

Market Cap

8.0B

Sector

Health Care

ML Signal

HOLD

Logo Kinsale Capital Group Inc.

KNSL

Kinsale Capital Group Inc.

HOLD

Current Price

$397.48

Market Cap

8.8B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CYTK
KNSL
Founded
1997
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
8.0B
8.8B
IPO Year
2004
2016

Fundamental Metrics

Financial Performance
Metric
CYTK
KNSL
Price
$62.51
$397.48
Analyst Decision
Strong Buy
Buy
Analyst Count
16
10
Target Price
$78.94
$483.78
AVG Volume (30 Days)
1.7M
267.0K
Earning Date
11-05-2025
10-23-2025
Dividend Yield
N/A
0.17%
EPS Growth
N/A
16.09
EPS
N/A
20.35
Revenue
$87,211,000.00
$1,802,839,000.00
Revenue This Year
$361.33
$19.56
Revenue Next Year
$65.14
$7.74
P/E Ratio
N/A
$19.62
Revenue Growth
2609.26
18.10
52 Week Low
$29.31
$349.00
52 Week High
$69.33
$512.76

Technical Indicators

Market Signals
Indicator
CYTK
KNSL
Relative Strength Index (RSI) 49.62 56.15
Support Level $59.37 $377.46
Resistance Level $63.80 $401.15
Average True Range (ATR) 2.56 11.11
MACD -0.44 4.34
Stochastic Oscillator 42.46 94.90

Price Performance

Historical Comparison
CYTK
KNSL

About CYTK Cytokinetics Incorporated

Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.

About KNSL Kinsale Capital Group Inc.

Kinsale Capital Group Inc is an insurance holding company. The company is engaged in offering property, casualty, and specialty insurance products. It offers specialty insurance products for allied health, healthcare, life sciences, professional, and a public entity. The company operates in only one reportable segment which is the Excess and Surplus Lines Insurance segment, which includes commercial excess and surplus lines liability and property insurance products through its underwriting divisions. The company generates revenues in the form of premiums and investment income.

Share on Social Networks: